insights_auto
Varför har LGND gått upp 3,09%?
Gå på djupetchevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
311,13 US$
arrow_upward
+3,09%(+9,32) 1 d
311,13 US$
0,00% (0,00)
bedtimeEfter stängning
Stängd: 12 okt., 16:00:02 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för LGND …
Öppen
302,50 US$
Högt
311,86 US$
Lågt
300,00 US$
Börsvärde
6,20 md
Genomsn. vol.
246,60 tn
Volym
173,18 tn
P/E-tal
33,09
52v högst
326,63 US$
52v lägst
175,89 US$
EPS
9,40 US$
Beta
1,06
Utestående aktier
19,94 mn
Antal anställda
47
Öppen
302,50 US$
Högt
311,86 US$
Lågt
300,00 US$
Börsvärde
6,20 md
Genomsn. vol.
246,60 tn
Volym
173,18 tn
P/E-tal
33,09
52v högst
326,63 US$
52v lägst
175,89 US$
EPS
9,40 US$
Beta
1,06
Utestående aktier
19,94 mn
Antal anställda
47
Nyheter och artiklar
Från webbkällor och nyhetspartner
Investing.com Nigeria
·
för 1 dag sedan
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com
Profil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Om Ligand Pharmaceuticals Inc